ClinicalTrials.Veeva

Find clinical trials for Acute Myeloid Leukemia (AML) in Valencia, VC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Valencia, VC, ESP:

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: LoDAC (Low Dose Cytarabine)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)

Phase 3

Astellas
Astellas

Valencia, Spain and 125 other locations

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Other: Best Supportive Care (BSC)
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Madrid, Spain and 164 other locations

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (APTIVATE)

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute...

Enrolling
Relapsed or Refractory Acute Myeloid Leukemia
Drug: Tuspetinib
Drug: Venetoclax Oral Tablet

Phase 1, Phase 2

Aptose Biosciences

Valencia, Spain and 33 other locations

A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS

two-part study to determine recommended phase 2 dose (RP2D) and schedule of GSK3745417 administration in participants with relapsed/refractory AML...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: GSK3745417

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Valencia, Spain and 10 other locations

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Valencia, Valenciana, Spain and 108 other locations

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

[GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who...

Enrolling
Acute Myeloid Leukemia
Drug: Fludarabine
Drug: Cytarabine

Phase 3

LLS PedAL Initiative, LLC

València, Spain and 71 other locations

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. ...

Active, not recruiting
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Acute Myeloid Leukemia (AML)
Drug: gilteritinib
Drug: azacitidine

Phase 3

Astellas
Astellas

Valencia, Spain and 110 other locations

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission (QUAZAR AML-001)

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) ...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine

Phase 3

Celgene
Celgene

Valencia, Spain and 222 other locations

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

of NMS-03592088 in adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocy...

Enrolling
Acute Myeloid Leukemia (AML)
Chronic Myelomonocytic Leukemia (CMML)
Drug: NMS-03592088

Phase 1, Phase 2

Nerviano Medical Sciences

Valencia, Spain and 16 other locations

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who ar...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Decitabine and Cedazuridine (ASTX727)

Phase 1, Phase 2

Astex Pharmaceuticals
Astex Pharmaceuticals

Valencia, Spain and 33 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems